Emerging Business Models in the Pharmaceutical Industries ...
Emerging Business Models in the Pharmaceutical Industries ...
Emerging Business Models in the Pharmaceutical Industries ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Overview<br />
Pharma companies are position<strong>in</strong>g<br />
<strong>the</strong>mselves on <strong>the</strong> basis of <strong>the</strong> size of <strong>the</strong>ir<br />
portfolio and R&D capabilities. Superpharma<br />
refers to <strong>the</strong> Big Pharma companies while<br />
supernet is <strong>the</strong> league of small and Big<br />
Pharma companies based on <strong>the</strong>ir<br />
market<strong>in</strong>g reach, companies are position<strong>in</strong>g<br />
<strong>the</strong>mselves as upstream or downstream<br />
companies.<br />
Companies with greater market<strong>in</strong>g reach are<br />
gett<strong>in</strong>g <strong>in</strong>to downstream drugs and pharma<br />
products. Companies with strong R&D and<br />
limited market research prefer to focus on<br />
upstream products.<br />
Patent Expiration and <strong>Emerg<strong>in</strong>g</strong> Generic<br />
Model<br />
The fight between generic and patented<br />
drugs has led pharma companies to explore<br />
new market segments for drugs with<br />
reduced R&D lifecycles. Big Pharma<br />
companies are turn<strong>in</strong>g to <strong>the</strong> network model<br />
of <strong>in</strong>-licens<strong>in</strong>g and out-licens<strong>in</strong>g to avoid<br />
problems aris<strong>in</strong>g from <strong>the</strong> expiry of patents,<br />
and reta<strong>in</strong> <strong>the</strong>ir los<strong>in</strong>g revenues. Smaller<br />
companies enter<strong>in</strong>g <strong>the</strong> generic market are<br />
try<strong>in</strong>g to claim a larger market share <strong>in</strong> <strong>the</strong><br />
North American and European markets.<br />
Dynamic Shifts <strong>in</strong> <strong>the</strong> Pharma Market<br />
Upstream<br />
vs.<br />
Downstream<br />
SuperPharma<br />
Industry Smaller<br />
vs.<br />
Classification vs.<br />
M&A<br />
SuperNet<br />
Big Pharma<br />
Bulk<br />
vs.<br />
Specialty<br />
Brand<br />
Equalisation<br />
Patents to<br />
Biotech<br />
Dynamic Shift <strong>in</strong> Pharma Market<br />
Source: JSB Intelligence<br />
Market Dynamics<br />
Patents<br />
Patent to<br />
Generic<br />
In-licens<strong>in</strong>g<br />
Vs<br />
Out-licens<strong>in</strong>g<br />
Outsourc<strong>in</strong>g<br />
Internationalisation<br />
vs.<br />
Localization<br />
Geographical<br />
Shift<br />
Parallel Trade<br />
Govt. Role<br />
Strategic Analysis of <strong>the</strong> Pharma Market, Future Revenue <strong>Models</strong> and Key Players 14
Change language